Quan MJ, Lin Q. Prognostic value of post-neoadjuvant immunochemotherapy hypercoagulation in gastric cancer patients undergoing surgery. World J Gastrointest Oncol 2025; 17(6): 105085 [PMID: 40547152 DOI: 10.4251/wjgo.v17.i6.105085]
Corresponding Author of This Article
Qiang Lin, MD, PhD, Professor, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, No. 8 Huizhan Avenue, Renqiu 062552, Hebei Province, China. billhappy001@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 105085 Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.105085
Prognostic value of post-neoadjuvant immunochemotherapy hypercoagulation in gastric cancer patients undergoing surgery
Meng-Jie Quan, Qiang Lin
Meng-Jie Quan, Qiang Lin, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu 062552, Hebei Province, China
Author contributions: Quan MJ wrote the manuscript; Lin Q conceived and designed the study, and revised the manuscript. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All authors declare that there is no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiang Lin, MD, PhD, Professor, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, No. 8 Huizhan Avenue, Renqiu 062552, Hebei Province, China. billhappy001@163.com
Received: January 15, 2025 Revised: April 1, 2025 Accepted: April 10, 2025 Published online: June 15, 2025 Processing time: 150 Days and 3.7 Hours
Abstract
There is no standard treatment for patients with locally advanced gastric cancer (LAGC). Neoadjuvant immunochemotherapy (NICT) is an emerging therapeutic strategy in LAGC. The prognosis of patients undergoing NICT plus radical surgery varies. Hypercoagulation is frequently identified in cancer patients. A retrospective study by Li et al confirmed that in LAGC patients undergoing radical resection post-NICT, elevated D-dimer and fibrinogen levels were associated with poor prognosis, and their combined assessment improved predictive accuracy. This retrospective study has some limitations, and further prospective research is required to validate hypercoagulation as a prognostic indicator and develop a more precise predictive model. Establishing such a model can facilitate personalized treatment strategies for patients with LAGC.
Core Tip: The prognosis of patients with locally advanced gastric cancer undergoing neoadjuvant immunochemotherapy (NICT) plus radical surgery varies. Post-NICT hypercoagulation may act as a prognostic indicator. However, standardized methods for assessing cancer-associated hypercoagulation are lacking. Future research should concentrate on identifying more precise and efficient biomarkers for assessing cancer-associated hypercoagulation to refine prognostic evaluation and guide individualized treatment.
